X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs VENUS REMEDIES - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. VENUS REMEDIES FRESENIUS KABI ONCO./
VENUS REMEDIES
 
P/E (TTM) x 22.1 -8.9 - View Chart
P/BV x 3.1 0.1 2,240.6% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   VENUS REMEDIES
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
VENUS REMEDIES
Mar-17
FRESENIUS KABI ONCO./
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs176143 123.2%   
Low Rs7965 120.8%   
Sales per share (Unadj.) Rs37.7324.2 11.6%  
Earnings per share (Unadj.) Rs5.16.4 79.5%  
Cash flow per share (Unadj.) Rs6.740.6 16.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5366.0 11.6%  
Shares outstanding (eoy) m158.2312.34 1,282.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.3 1,053.5%   
Avg P/E ratio x25.016.2 154.1%  
P/CF ratio (eoy) x18.92.6 739.2%  
Price / Book Value ratio x3.00.3 1,053.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1351,282 1,570.4%   
No. of employees `0001.20.9 127.6%   
Total wages/salary Rs m703251 280.2%   
Avg. sales/employee Rs Th5,176.24,430.1 116.8%   
Avg. wages/employee Rs Th610.4278.0 219.6%   
Avg. net profit/employee Rs Th699.687.6 798.6%   
INCOME DATA
Net Sales Rs m5,9634,000 149.1%  
Other income Rs m1823 79.3%   
Total revenues Rs m5,9814,023 148.7%   
Gross profit Rs m1,430785 182.2%  
Depreciation Rs m258422 61.2%   
Interest Rs m-26344 -7.6%   
Profit before tax Rs m1,21642 2,888.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-37 -924.9%   
Profit after tax Rs m80679 1,018.8%  
Gross profit margin %24.019.6 122.3%  
Effective tax rate %28.1-87.9 -32.0%   
Net profit margin %13.52.0 683.5%  
BALANCE SHEET DATA
Current assets Rs m5,1022,606 195.7%   
Current liabilities Rs m2,3851,980 120.5%   
Net working cap to sales %45.615.6 291.1%  
Current ratio x2.11.3 162.5%  
Inventory Days Days150128 116.9%  
Debtors Days Days11343 262.6%  
Net fixed assets Rs m5,1485,353 96.2%   
Share capital Rs m158123 128.2%   
"Free" reserves Rs m6,5564,393 149.2%   
Net worth Rs m6,7324,516 149.1%   
Long term debt Rs m9521,618 58.8%   
Total assets Rs m10,3888,291 125.3%  
Interest coverage x-45.81.1 -4,078.2%   
Debt to equity ratio x0.10.4 39.5%  
Sales to assets ratio x0.60.5 119.0%   
Return on assets %7.55.1 147.2%  
Return on equity %12.01.8 683.5%  
Return on capital %14.66.3 232.2%  
Exports to sales %74.50-   
Imports to sales %24.818.4 134.6%   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477736 200.6%   
Fx inflow Rs m5,2980-   
Fx outflow Rs m1,772736 240.7%   
Net fx Rs m3,525-736 -478.8%   
CASH FLOW
From Operations Rs m1,274997 127.8%  
From Investments Rs m-1,204-461 261.0%  
From Financial Activity Rs m-196-571 34.3%  
Net Cashflow Rs m-126-35 359.8%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.2 166.7%  
FIIs % 9.6 0.6 1,655.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 66.4 13.7%  
Shareholders   42,599 20,121 211.7%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - JUBILANT LIFE SCIENCES COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS